Biocon has been granted a patent for a method to generate bispecific chimeric fusion proteins for cancer therapy. These proteins target EGFR1 and PD-L1, combining a targeting moiety and an immunomodulatory moiety to enhance immune response against cancer cells. GlobalData’s report on Biocon gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Biocon, Hormone-based therapies for metabolic disorders was a key innovation area identified from patents. Biocon's grant share as of July 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Bispecific chimeric fusion protein for cancer therapy
The granted patent US12049632B2 outlines a method for the binding of a bispecific chimeric fusion protein to two specific targets: EGFR1 and PD-L1. This method involves the interaction of the bispecific chimeric fusion protein with both targets, facilitated by a targeting moiety and an immunomodulating moiety. The targeting moiety is identified as an anti-EGFR1 antibody, which consists of a heavy chain and a light chain defined by specific amino acid sequences (SEQ ID NO: 5 and SEQ ID NO: 6). The immunomodulating moiety is designated as PD1, represented by SEQ ID NO: 10. These two moieties are connected by an amino acid spacer, which is selected from either SEQ ID NO: 3 or SEQ ID NO: 11, ensuring that both moieties can effectively bind to their respective targets.
Additionally, the patent claims that the immunomodulating moiety (PD1) is capable of binding to PD-L1, thereby counteracting immune tolerance. The chimeric fusion protein is characterized by the specific linkage of the targeting and immunomodulating moieties through the amino acid spacer, which is crucial for maintaining the functional integrity of the protein. The claims emphasize the structural components and specific sequences involved in the design of the bispecific chimeric fusion protein, highlighting its potential applications in therapeutic contexts where modulation of immune responses is desired.
To know more about GlobalData’s detailed insights on Biocon, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
